Table 1.

Antagonist activity of AGN 204396 at various concentrations and AL-8810 ethylamide at 3 × 10⁻⁵ M in the feline iris

Agonist vs antagonist identity	Agonist log EC50±s.d. in the presence of vehicle	Agonist log EC50±s.d. in the presence of antagonist	P-Value (comparing agonist EC50 in the presence and absence of antagonist)
AGN 204396 1 × 10−6 M vs prostamide F2α	−7.365±0.066	−7.150±0.063	0.224 NS
AGN 204396 3 × 10−6 M vs prostamide F2α	−7.065±0.039	−6.713±0.068	<0.0001***
AGN 204396 6 × 10−6 M vs prostamide F2α	−7. 220±0.050	−6.622±0.112	<0.0001***
AGN 204396 1 × 10−5 M vs prostamide F2α	−7.096±0.042	−6.429±0.054	<0.0001***
AGN 204396 2 × 10−5 M vs prostamide F2α	−7.237±0.068	−6.210±0.050	<0.0001***
AGN 204396 3 × 10−5 M vs prostamide F2α	−7.116±0.059	−6.068±0.055	<0.0001***
AGN 204396 3 × 10−5 M vs PGF2α	−7.780±0.026	−7.780±0.080	0.8722 NS
AGN 204396 1 × 10−5 M vs bimatoprost	−7.819±0.057	−7.084±0.037	<0.0001***
AGN 204396 3 × 10−5 M vs bimatoprost	−7.654±0.052	−6.828±0.065	<0.0001***
AGN 204396 1 × 10−5 M vs 17-phenyl PGF2α	−8.699±0.053	−8.616±0.080	0.3962 NS
AGN 204396 3 × 10−5 M vs 17-phenyl PGF2α	−8.127±0.068	−8.055±0.063	0.4390 NS
AGN 204396 3 × 10−5 M vs fluprostenol	−8.658±0.049	−8.562±0.049	0.1727 NS
AGN 204396 3 × 10−5 M vs latanoprost free acid	−7.900±0.092	−7.905±0.087	0.9711 NS
AGN 204396 3 × 10−5 M vs prostamide D2	−6.259±0.046	−5.302±0.070	<0.001**
AGN 204396 3 × 10−5 M vs PGD2	−7.042±0.069	−6.979±0.042	0.4376 NS
AGN 204396 3 × 10−5 M vs Prostamide E2	−6.049±0.049	−4.999±0.060	<0.0001***
AGN 204396 3 × 10−5 M vs PGE2	−6.500±0.056	−6.126±0.059	<0.0001***
AGN 204396 3 × 10−5 M vs PGE2 - glyceryl ester	−6.155±0.037	−6.174±0.033	0.7161 NS
AGN 204396 3 × 10−5 M vs AL-8810	−5.167±0.079	−5.079±0.069	0.4175 NS
AL-8810 Ethylamide 3 × 10−5 M vs Prostamide F2α	−7.100±0.072	−7.093±0.047	0.9350 NS

Abbreviation: NS=non significant.

Values and log EC₅₀±s.d.. n=6 for all studies;

^**P<0.01

^***P<0.0001.